[
  {
    "ts": null,
    "headline": "AstraZeneca Strikes Drug-Pricing Deal With Trump Administration",
    "summary": "The agreement, which entails offering “most-favored nation” pricing, follows Pfizer’s deal to reduce prices for its drugs sold in the Medicaid program and through a direct-purchasing service to be branded TrumpRx.",
    "url": "https://finnhub.io/api/news?id=78f4394e58d42f0b0a3fd285a0bacfb579cb04f8118f7d4f78bffdbee36ce6fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760137860,
      "headline": "AstraZeneca Strikes Drug-Pricing Deal With Trump Administration",
      "id": 137049166,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The agreement, which entails offering “most-favored nation” pricing, follows Pfizer’s deal to reduce prices for its drugs sold in the Medicaid program and through a direct-purchasing service to be branded TrumpRx.",
      "url": "https://finnhub.io/api/news?id=78f4394e58d42f0b0a3fd285a0bacfb579cb04f8118f7d4f78bffdbee36ce6fe"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Maintains Pfizer (PFE) Equal-Weight Recommendation",
    "summary": "Morgan Stanley Maintains Pfizer (PFE) Equal-Weight Recommendation",
    "url": "https://finnhub.io/api/news?id=ade2a309b8847884be9cf668aa9c8bfad0706f5418457009abc79b45e3e1b916",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760136016,
      "headline": "Morgan Stanley Maintains Pfizer (PFE) Equal-Weight Recommendation",
      "id": 137045796,
      "image": "",
      "related": "PFE",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=ade2a309b8847884be9cf668aa9c8bfad0706f5418457009abc79b45e3e1b916"
    }
  },
  {
    "ts": null,
    "headline": "Trump Announces AstraZeneca Drug Price Cuts for Tariff Reprieve",
    "summary": "“AstraZeneca, the largest pharmaceutical manufacturer in the United Kingdom, is committing to offer Americans major discounts on their vast catalog of prescription drugs,” Trump said Friday in the Oval Office, where he was joined by AstraZeneca Chief Executive Officer Pascal Soriot.  The deal — similar to a pact announced last week by Pfizer Inc. — will see AstraZeneca slash what it charges for its medicines in exchange for three years of relief from threatened tariffs on the pharmaceutical industry.",
    "url": "https://finnhub.io/api/news?id=3f72c0b7e0d9c373f702ec53e3ee2e2a04005b939f915a995ed04a63e287c347",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760133495,
      "headline": "Trump Announces AstraZeneca Drug Price Cuts for Tariff Reprieve",
      "id": 137049167,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "“AstraZeneca, the largest pharmaceutical manufacturer in the United Kingdom, is committing to offer Americans major discounts on their vast catalog of prescription drugs,” Trump said Friday in the Oval Office, where he was joined by AstraZeneca Chief Executive Officer Pascal Soriot.  The deal — similar to a pact announced last week by Pfizer Inc. — will see AstraZeneca slash what it charges for its medicines in exchange for three years of relief from threatened tariffs on the pharmaceutical industry.",
      "url": "https://finnhub.io/api/news?id=3f72c0b7e0d9c373f702ec53e3ee2e2a04005b939f915a995ed04a63e287c347"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stocks Have Struggled Since 2021. Why They’re Coming Back.",
    "summary": "Biotech Stocks Have Struggled Since 2021. Why They’re Coming Back.",
    "url": "https://finnhub.io/api/news?id=b0934288cce7da9c2bbf2e835b824d0a6d51735a812691879b64b6565ec755fc",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760127480,
      "headline": "Biotech Stocks Have Struggled Since 2021. Why They’re Coming Back.",
      "id": 137078172,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Biotech Stocks Have Struggled Since 2021. Why They’re Coming Back.",
      "url": "https://finnhub.io/api/news?id=b0934288cce7da9c2bbf2e835b824d0a6d51735a812691879b64b6565ec755fc"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca becomes latest drugmaker to strike deal with Trump. Its stock is climbing after hours.",
    "summary": "AstraZeneca becomes latest drugmaker to strike deal with Trump. Its stock is climbing after hours.",
    "url": "https://finnhub.io/api/news?id=0d117fd85f3f447cb7f75dec88617f8462064b36a3e3e1cafc2fa7a02d4dffb3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760119740,
      "headline": "AstraZeneca becomes latest drugmaker to strike deal with Trump. Its stock is climbing after hours.",
      "id": 137110309,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "AstraZeneca becomes latest drugmaker to strike deal with Trump. Its stock is climbing after hours.",
      "url": "https://finnhub.io/api/news?id=0d117fd85f3f447cb7f75dec88617f8462064b36a3e3e1cafc2fa7a02d4dffb3"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going.",
    "summary": "The recent cavalcade of biotech deals continued Friday morning, when  Bristol Myers Squibb  said it had agreed to pay $1.5 billion to acquire Orbital Therapeutics, an early-stage, privately held biotech designing RNA-based medicines.  Its lead program, a potential treatment for autoimmune conditions called OTX-201, isn’t expected to enter human trials until next year.  The Orbital deal is Bristol’s largest since February 2024, when it closed a $4.1 billion acquisition of RayzeBio, a cancer-focused biotech.",
    "url": "https://finnhub.io/api/news?id=7d6a7d87f2d7d4a5725b458303ab18f2cf290aff6d4a485d575f23dc5f813107",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760113140,
      "headline": "Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going.",
      "id": 137043167,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The recent cavalcade of biotech deals continued Friday morning, when  Bristol Myers Squibb  said it had agreed to pay $1.5 billion to acquire Orbital Therapeutics, an early-stage, privately held biotech designing RNA-based medicines.  Its lead program, a potential treatment for autoimmune conditions called OTX-201, isn’t expected to enter human trials until next year.  The Orbital deal is Bristol’s largest since February 2024, when it closed a $4.1 billion acquisition of RayzeBio, a cancer-focused biotech.",
      "url": "https://finnhub.io/api/news?id=7d6a7d87f2d7d4a5725b458303ab18f2cf290aff6d4a485d575f23dc5f813107"
    }
  },
  {
    "ts": null,
    "headline": "2 Pharmaceutical Stocks That Look Like No-Brainer Buys Right Now",
    "summary": "Ongoing developments make these companies look attractive.",
    "url": "https://finnhub.io/api/news?id=19ef1109a85f693167077a598e9cea46836df8a900288540e841dc7f2b1fe99b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760093100,
      "headline": "2 Pharmaceutical Stocks That Look Like No-Brainer Buys Right Now",
      "id": 137041434,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Ongoing developments make these companies look attractive.",
      "url": "https://finnhub.io/api/news?id=19ef1109a85f693167077a598e9cea46836df8a900288540e841dc7f2b1fe99b"
    }
  },
  {
    "ts": null,
    "headline": "Pharma R&D set to endure despite rising MFN costs",
    "summary": "MFN-driven drug price reductions are unlikely to impact pharma R&D spending.",
    "url": "https://finnhub.io/api/news?id=aaa0c0415ce62ca3f9389f8fed23f7b7a7850f8d9244dd03810972f57bf3f9cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760088734,
      "headline": "Pharma R&D set to endure despite rising MFN costs",
      "id": 137041436,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "MFN-driven drug price reductions are unlikely to impact pharma R&D spending.",
      "url": "https://finnhub.io/api/news?id=aaa0c0415ce62ca3f9389f8fed23f7b7a7850f8d9244dd03810972f57bf3f9cd"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's Q3: The Catalyst For A Bullish Resurgence (Earnings Preview)",
    "summary": "Pfizer's Q3: The Catalyst For A Bullish Resurgence (Earnings Preview)",
    "url": "https://finnhub.io/api/news?id=66a9b1ce34337bb89092d7449ea01fb338517a234869a3ea2312a2c661be530e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760086821,
      "headline": "Pfizer's Q3: The Catalyst For A Bullish Resurgence (Earnings Preview)",
      "id": 137040572,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=66a9b1ce34337bb89092d7449ea01fb338517a234869a3ea2312a2c661be530e"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: A Safe Haven That's Quietly Becoming A Bit Overpriced",
    "summary": "Johnson & Johnson is currently overvalued, with limited upside and mid-to-high single-digit long-term return potential amid ongoing sector risks. See why JNJ stock is a Hold.",
    "url": "https://finnhub.io/api/news?id=deb2c680d3ed21229cdd1b78c9fd8288f8598fe15ccff4e8ffdb6af3285956ec",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760082523,
      "headline": "Johnson & Johnson: A Safe Haven That's Quietly Becoming A Bit Overpriced",
      "id": 137040347,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1428797069/image_1428797069.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson is currently overvalued, with limited upside and mid-to-high single-digit long-term return potential amid ongoing sector risks. See why JNJ stock is a Hold.",
      "url": "https://finnhub.io/api/news?id=deb2c680d3ed21229cdd1b78c9fd8288f8598fe15ccff4e8ffdb6af3285956ec"
    }
  },
  {
    "ts": null,
    "headline": "Here's How This Pharmaceutical Giant Is Protecting Itself From President Trump's Tariffs. Should It Matter to Investors?",
    "summary": "A new deal with the White House could lead to a new sales channel that bypasses health insurance companies.",
    "url": "https://finnhub.io/api/news?id=8b353764c1e6845e4e373f33ce25d5214904e2cdc187c2201df029d3b8a4d2ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760080680,
      "headline": "Here's How This Pharmaceutical Giant Is Protecting Itself From President Trump's Tariffs. Should It Matter to Investors?",
      "id": 137041822,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "A new deal with the White House could lead to a new sales channel that bypasses health insurance companies.",
      "url": "https://finnhub.io/api/news?id=8b353764c1e6845e4e373f33ce25d5214904e2cdc187c2201df029d3b8a4d2ae"
    }
  }
]